Clin Lab. 2023 Oct 1;69(10). doi: 10.7754/Clin.Lab.2023.230435.
We present the case study of a 28-year-old pregnant woman with antithrombin deficiency who was treated with low-molecular-weight heparin (LMWH).
Due to severe homozygous type II antithrombin heparin binding site (HBS) deficiency, the thrombin generation (TG) was monitored in this woman via the Thrombin Generation Assay (TGA). We used Siemens diagnostic kits Berichrom® Antithrombin III (IIa) and INNOVANCE® Antithrombin (Xa) to determine antithrombin activity. We used a chromogenic method for determination of factor Xa (FXa) inhibition.
There were no thrombotic complications during the whole pregnancy of the observed woman. Antithrombin was administered before and after delivery, which was significantly reflected in the decrease in thrombin generation.
Consistent monitoring of thrombin generation with LMWH anticoagulant therapy administration during pregnancy together with antithrombin administration before and after delivery can improve the overall condition of pregnant women and the quality of their care.
我们报告了一例 28 岁妊娠合并抗凝血酶缺乏症患者，该患者接受了低分子肝素（LMWH）治疗。
由于存在严重的纯合子 II 型抗凝血酶肝素结合位点（HBS）缺乏，我们通过血栓生成分析（TGA）监测该患者的凝血酶生成（TG）。我们使用西门子诊断试剂盒 Berichrom® Antithrombin III（IIa）和 INNOVANCE® Antithrombin（Xa）来确定抗凝血酶活性。我们使用显色法来测定因子 Xa（FXa）抑制。
在观察到的女性整个怀孕期间均未发生血栓并发症。在分娩前后给予了抗凝血酶，这明显反映在血栓生成减少。
在妊娠期间用 LMWH 抗凝治疗给药并在分娩前后给予抗凝血酶时，持续监测血栓生成可以改善孕妇的整体状况并提高护理质量。
